ITASCA, Ill. and SYDNEY, Australia, May 28 /PRNewswire-FirstCall/ -- A new study of more than 10,000 patients, conducted by the Universities of Cambridge and Cardiff in the United Kingdom using AtCor Medical Holdings Limited's SphygmoCor(R) has found that more than 70 percent of patients identified as having "high normal" systolic blood pressure through traditional cuff blood pressure measurement may be at serious cardiovascular risk. This is because those individuals have elevated central systolic blood pressure, which is associated with increased incidence of heart attack, stroke and kidney disease. SphygmoCor(R) is a non-invasive central blood pressure assessment technology that has been used by researchers over the past several years.

FRAMINGHAM, Mass., May 28 /PRNewswire/ -- A new study reveals that shopping and discovering an unbelievable fashion find produces a euphoric experience greater than sky diving, kissing or eating chocolate -- increasing heart rates to 192 beats per minute, more than triple the normal resting heart rate of 60. While it has long been known that many women enjoy shopping -- it is something they do willingly and often -- now there is evidence that shopping does actually bring physical happiness. The research, conducted by renowned researcher Dr. David Lewis of the MindLab International on behalf of T.J. Maxx, scientifically reveals that finding a bargain is in fact, a euphoric experience that did not occur in women shopping a department, discount and specialty store.

LEBANON, N.J., May 28 /PRNewswire/ -- Orphan Therapeutics today announced that it has begun submission of the rolling LUCASSIN(R) (terlipressin) New Drug Application (NDA) for the treatment of hepatorenal syndrome (HRS) type 1 in patients with late-stage liver cirrhosis. LUCASSIN(R) had previously been granted orphan status and fast track designation for this indication by the U.S. Food and Drug Administration (FDA). Currently no drug is approved in the U.S. to treat HRS type 1, a rare and life-threatening condition in late-stage liver disease.

MOUNTAINSIDE, N.J., May 28 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC: NHGI - News) today announced that it is taking steps to change its name to Proteonomix, Inc. The change will also entail a change in its trading symbol.

PORTLAND, Ore., May 28 /PRNewswire/ -- Today, Dr. F. Douglas Day, M.D., Founder and Medical Director of Day Medical Salon, announced the launch of the Oregon Cosmetic Vein Center (OCVC). The OCVC (http://www.oregoncosmeticveincenter.com) is one of the first West Coast vein clinics to offer the CoolTouch CTEV(R) Vein Removal Procedure and other new, FDA-approved treatments and technologies. The OCVC's investment in the very latest equipment and training delivers better results in fewer visits, a potential savings of money, time and discomfort for clients. The OCVC is conveniently located in the medical suites on the third floor of Portland's Lloyd Center Mall.

ANN ARBOR, Mich., May 28 /PRNewswire/ -- Three studies to be reported at the American Society of Clinical Oncology (ASCO) Annual Meeting used Thomson Reuters Cancer Profiler tools to gain insights into the adverse effects of treatment for head and neck cancers and lung cancer.

FREDERICK, Md., May 28 /PRNewswire-FirstCall/ -- BioElectronics Corp. (Pink Sheets: BIEL), the maker of the ActiPatch(TM), a drug free anti- inflammatory patch, with an embedded battery operated microchip delivering continuous pulse therapy specifically designed to speed healing, today announced world renowned plastic surgeon David G. Genecov will develop, institute and complete research studies on post-operative management of breast augmentation and cesarean section procedures. Both double blind randomized studies will be done in conjunction with other leading surgeons, obstetricians and gynecologists under Dr. Genecov's direction and supervision.

NASHVILLE, Tenn., May 28 /PRNewswire/ -- HealthLeaders-InterStudy, a leading provider of healthcare market intelligence, reports that the collapse of the auction-rate securities market is triggering major cost increases for health systems that have borrowed money to undertake facility expansions. According to the latest Phoenix Market Overview, problems securing reasonable interest rates for variable-rate bonds have forced hospitals to refinance.

Austin Orthopedics and Sports Medicine has opened a new 4,200-square-foot office at Post Oak Center North Building 1, 2200 Park Bend Drive, across the street from the North Austin Medical Center in Austin, TX. Run by Kalin D. Kelso, M.D., a board-certified orthopedic surgeon, the single specialty practice will provide total management of patient care and the full range of orthopedic services, including sports medicine, on-site physical therapy and radiology. Kelso is the first tenant partner since Oaks Development Group converted the 29,724-square-foot Class A medical office building to its unique ownership hybrid.

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the appointment of four additional members to its Clinical Advisory Board to help guide the Company's expanding clinical development strategy for picoplatin. They include Howard A. Burris, III, M.D., of The Sarah Cannon Research Institute in Nashville; E. David Crawford, M.D., of the University of Colorado Comprehensive Cancer Center; Robert F. Ozols, M.D., Ph.D., of the Fox Chase Cancer Center in Philadelphia; and Everett E. Vokes, M.D., of the University of Chicago Pritzker School of Medicine.